Vaccination News Home Page

http://www.pediatrics.org/cgi/content/abstract/110/6/e71

Full Text of this Article Reprint (PDF) Version of this Article P3Rs: Submit a response to this article Similar articles found in: Pediatrics Online PubMed PubMed Citation Search Medline for articles by: Pool, V. || Gargiullo, P. M. Alert me when: new articles cite this article   Download to Citation Manager

Collections under which this article appears: Infectious Disease & Immunity

PEDIATRICS Vol. 110 No. 6 December 2002, pp. e71

 

Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States

Vitali Pool, MD^*, M. Miles Braun, MD, MPH, John M. Kelso, MD, Gina Mootrey, DO, MPH^*, Robert T. Chen, MD, MA^*, John W. Yunginger, MD^||, Robert M. Jacobson, MD^¶ and Paul M. Gargiullo, PhD^# the VAERS Team

^* Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia
Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland
Department of Internal Medicine (Allergy Division), Naval Medical Center, San Diego, California
^|| Allergic Diseases Research Laboratory
^¶ Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, Minnesota
^# Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

Objective. Anaphylaxis after immunization, although rare, is serious and potentially life-threatening. Understanding risk factors for this reaction is therefore important. Gelatin is added to many vaccines as a heat stabilizer. Japanese researchers have demonstrated a strong association between immediate hypersensitivity reactions to measles, mumps, rubella, varicella, and Japanese encephalitis immunizations and subsequent detection of anti-gelatin immunoglobulin E (IgE) antibodies. They suggested that previous receipt by these patients of diphtheria-tetanus-acellular pertussis vaccines with trace amounts of gelatin was responsible for the sensitization. We aimed to assess whether a similar association exists for vaccinees in the United States who reported anaphylaxis after receipt of measles-mumps-rubella (MMR) or measles vaccines and to review recent trends in reporting of hypersensitivity reactions.

Methods. We conducted a retrospective case-control study. Cases of anaphylaxis that met a predefined case definition were identified from the US Vaccine Adverse Event Reporting System (VAERS). Mayo Clinic patients who received MMR vaccine uneventfully served as controls. The study subjects were interviewed to obtain the history of allergies. Sera from study subjects and their matched controls were tested for IgE antibodies to gelatin, whole egg, and vaccine viral antigens using solid-phase radioimmunoassay. Data from the Biologics Surveillance System on annual numbers of doses of MMR and varicella vaccines distributed in the United States were used to evaluate possible changes in reporting of selected allergic adverse events.

Results. Fifty-seven study subjects were recruited into the study and interviewed. Of these, 22 provided serum samples for IgE testing. Twenty-seven subjects served as a comparison group and provided a sample for IgE testing; 21 of these completed an allergy history questionnaire. Self-reported history of food allergies was present more frequently in the interviewed study subjects than in the controls, whereas the proportions of people with other characteristics were similar in both groups. None of the interviewed people had a history of food allergy to gelatin. The level of anti-gelatin IgE antibodies was significantly higher among study subjects than among controls, whereas the levels of IgE antibodies against egg and all 3 viral antigens did not differ significantly. Of 22 study subjects, 6 (27%) tested positive for anti-gelatin IgE, whereas none of the 27 controls did. The rate of anaphylactic reactions reported to VAERS after measles virus-containing immunization in the United States between 1991 and 1997 is 1.8 per 1 million doses distributed. No substantial increase in the number of reported allergic events after frequently used gelatin containing MMR and varicella vaccines could be observed during the first 4 years (1997–2000) since the introduction of diphtheria-tetanus-acellular pertussis vaccines for use in infancy.

Conclusion. Anaphylactic reactions to MMR in the United States are rare. The reporting rate has the same order of magnitude as estimates from other countries. Almost one fourth of patients with reported anaphylaxis after MMR seem to have hypersensitivity to gelatin in the vaccine. They may be at higher risk of developing anaphylaxis to subsequent doses of other gelatin-containing vaccines. These people should seek an allergy evaluation before such immunization.

Key Words: anaphylaxis • gelatin • measles-mumps-rubella vaccine • VAERS • vaccine adverse reactions

Abbreviations: MMR, measles-mumps-rubella • IgE, immunoglobulin E • DTaP, diphtheria-tetanus-acellular pertussis • CDC, Centers for Disease Control and Prevention • VAERS, Vaccine Adverse Event Reporting System • COSTART, Coding Symbols for Thesaurus of Adverse Reaction Terms • CPM, counts per minute • OPV, oral polio vaccine • HiB, Haemophilus influenzae type B

Received for publication Feb 11, 2002; accepted Aug 12, 2002.

Copyright © 2002 by the American Academy of Pediatrics. [Disclaimer]

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.